|Bid||38.04 x 3100|
|Ask||38.10 x 1400|
|Day's range||37.93 - 38.39|
|52-week range||27.88 - 40.97|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||15.07|
|Earnings date||27 Oct 2020 - 02 Nov 2020|
|Forward dividend & yield||1.52 (3.98%)|
|Ex-dividend date||30 Jul 2020|
|1y target est||41.85|
As of today, 167 COVID-19 vaccine candidates are in development around the world with 28 in clinical human trials. In response, demand for coronavirus vaccine stocks has soared as investors try to pick the most likely winners of the vaccine race. One of the most promising vaccine candidates is being jointly developed by two large-cap biotech companies, BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE).
Buy shares of a company that isn't profitable yet and doesn't even have consistent revenue. Inovio Pharmaceuticals (NASDAQ: INO) definitely fits the bill of a company that isn't generating a profit right now and doesn't have products on the market to generate a reliable revenue stream. Could Inovio be a millionaire-maker stock?
If Moderna (NASDAQ: MRNA) and its peers take too long to get their current coronavirus vaccine candidates fully developed and approved, they could pay the price. The government is mandating that they meet ambitious targets for this. Moderna, for example, will receive $1.5 billion from the government if its MRNA-1273 candidate is approved for use by Jan. 31, 2021.